对基于脂质和聚合物纳米的17-β-雌激醇输送系统的审查:进展和挑战
Mayara Munhoz de Assis Ramos1, Fernanda Yamamoto Ricardo-da-Silva1, Luiza de Oliveira Macedo2
1Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação (LIM-11), Instituto do Coração (INCOR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
概括
基于纳米的输送系统为17β-雌二醇 (E2) 的溶解性差提供了解决方案. 本综述探讨了用于增强E2治疗的脂质和聚合物纳米粒子的最新进展,突出了未来的研究需求.
科学领域:
- 内分泌学和生殖医学 繁殖医学
- 纳米技术和生物材料
- 药理学和药物输送 药理学和药物输送
背景情况:
- 17β-雌激醇 (E2) 是女性生殖健康的关键激素,其治疗用途超出了其生理作用.
- 由于配方挑战,E2的疏水性限制了其临床使用.
- 基于纳米的交付系统正在成为克服E2可溶性问题的可行策略.
研究的目的:
- 在过去十年中,批判性地审查17β-雌二醇 (E2) 的当代纳米输送策略.
- 专注于基于脂质和聚合物纳米粒子系统的E2封装和输送.
- 确定研究缺口,并倡导对纳米基E2疗法的进一步研究.
主要方法:
- 综合性文献综述,重点关注E2的基于纳米的交付系统.
- 在脂质和聚合物纳米颗粒中对封装技术的分析.
- 评估稳定性,生物相容性,受控释放和目标交付方面的进展.
主要成果:
- 基于纳米的系统,特别是脂质和聚合物纳米粒子,有望提高E2稳定性,生物相容性和受控释放.
- 这些纳米结构为提高E2治疗效率提供了潜力.
- 尽管取得了进展,但E2交付中的选择性仍然是一个重大挑战.
结论:
- 基于纳米的输送系统是克服17β-雌二醇 (E2) 管理局限性的有希望的途径.
- 进一步的研究和实验验证对于将这些纳米疗法转化为临床实践至关重要.
- 需要对E2纳米封装进行更深入的研究,以弥合研究和床边应用之间的差距.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
336
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
336
01:19Modified-Release Drug Delivery Systems: Overview
243
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
243
01:30Modified-Release Drug Delivery Systems: Bioavailability
177
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
177
01:23Modified-Release Drug Delivery Systems: Classification
318
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
318
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165
01:21Intrauterine Drug Delivery Systems
169
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
169